Year: 2024

– Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology – – Two new clinical trials, REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with rare leukemia, and REFRαME-L1, a Phase 2 trial of luvelta for patients with non-small cell lung cancer, are underway – – Sutro presented data from the Phase 1b study of luvelta in combination with bevacizumab at ESMO 2024 demonstrating a 56% response rate at the recommended Phase 2 dose of luvelta (4.3 mg/kg) – – As of September 30, 2024, Sutro had $388.3 million in cash, cash equivalents and marketable securities – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage...

MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2024 on Wednesday, November 20, 2024 before market opening. A presentation on the Company’s third quarter and year-to-date 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients....

Preliminary third quarter 2024 revenue to be approximately $113 million* Q3 materials grew 10% year-over-year and 9% sequentially, offset by declines in printer revenues driven by continued macro-related pressures on capital spending* Record year of product innovation and regulatory approvals supporting future growth in key markets such as Dental, Personalized Healthcare, Aerospace & Defense. This positions the company for exciting future revenue growth as the economy normalizes Management expects to release and discuss complete third quarter 2024 results the week of November 25, 2024*The preliminary financial data above and below remains subject to the company’s close process. Accordingly, actual results may differ from the anticipated results shown. ROCK HILL, S.C., Nov. 13, 2024 (GLOBE NEWSWIRE) — 3D Systems (NYSE:DDD)...

Company achieves positive Adjusted EBITDA* for the third consecutive quarter, reaching $0.9 million year-to-date, a $4.3 million improvement year-on-year Third-quarter operating expenses reduced by 44% year-on-year with year-to-date operating expenses down by 38% Existing debt obligation maturity extended to January 2027BOCA RATON, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) — SpringBig Holdings, Inc. (“Springbig” or the “Company”) (OTCQX: SBIG), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs, today announced its financial results for the third quarter ended September 30, 2024, and amendments to the terms of its debt obligations. “We are reporting a third quarter of positive Adjusted EBITDA*, and our eighth consecutive quarter of improving Adjusted EBITDA*. Our...

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.0 million, or $0.33 per diluted share, on net sales of $33.2 million for the first quarter of fiscal year 2025 compared to a net loss of $0.7 million, or $0.12 per diluted share, in the first quarter of the prior fiscal year. Net sales during the three months ended September 30, 2024, decreased $0.8 million, or 2.4%, to $33.2 million as compared to $34.0 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales decreased $1.6 million, a 4.8% decrease from the comparable quarter last year. Private-label contract manufacturing...

MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol ‘TLX’. The Company continues to have its primary listing on ASX, with the Nasdaq listing of ADSs expected to complement the Company’s ASX listing. Each ADS represents one fully paid ordinary share of the Company. Telix has not issued any new shares as part of the Nasdaq listing. Initial trading of ADSs may be limited as existing shareholders take time to transition their TLX shares to ADSs. JPMorgan Chase Bank. N.A. has been appointed as the depositary, custodian and registrar for the ADS program. Dr. Christian Behrenbruch, Managing Director and Group Chief Executive...